URBAN ARCH Uganda Cohort
Alcohol Drinkers’ Exposure to Preventive Therapy for TB (ADEPTT) will examine the safety and tolerability of tuberculosis (TB) preventive therapy for HIV-infected drinkers. The study will also estimate the level of adherence to TB preventive therapy overall, by month on therapy and by drinking level, and determine whether the clinical benefits of TB preventive therapy outweigh toxicity risks for HIV infected drinkers in resource limited settings.
Judith Hahn, PhD, MA
Associate Professor in Residence, Infectious Diseases, San Francisco General Hospital (SFGH), University of California, San Francisco (UCSF)
Debbie Cheng, ScD
Professor of Biostatistics, Boston University School of Public Health
Robin Fatch, MPH
Statistician/Data Manager, Infectious Diseases, Department of Medicine, UCSF
Monica Gandhi, MD, MPH
Professor of Medicine and Associate Division Chief of the Division of HIV, Infectious Diseases, and Global Medicine, UCSF School of Medicine
Karen Jacobson, MD, MPH
Assistant Professor of Medicine, Boston University School of Medicine, BUSM
Benjamin Linas, MD, MPH
Assistant Professor of Medicine and Director of HIV Epidemiology and Outcomes Research Unit, BUSM
Winnie Muyindike, MBChB, MMED
Director of ISS Clinic, Mbarara University of Science and Technology (MUST)
Study progress: The ADEPT-TB study is expected to begin participant recruitment and assessments in 2017. For more information, click here.
Recruitment Site: ISS HIV Clinic, Mbarara, Uganda
First Cycle (2011-2016) Original Uganda Cohort Grant Title: Impact of Heavy Alcohol Use on Pre-ART HIV Disease
The original Uganda Cohort aimed to assess the impact of heavy alcohol consumption on HIV disease progression, as measured by CD4 cell count decline among those not yet on ART in Mbarara, Uganda. Click here for additional information about the original Uganda Cohort. Click here to see baseline characteristics.